[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"inguinal-hernia-without-obstruction-or-gangrene\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:inguinal-hernia-without-obstruction-or-gangrene":56},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":10,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":30,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":45,"lastUpdatePostDateStruct":46,"startDateStruct":49,"completionDateStruct":51,"leadSponsor":53,"locationsCount":5},"100643499",false,"NCT07604272","Reversing InGuinal Hernia Trial: The Evaluation of Sex Hormones to Reverse Inguinal Hernias in Males","Reversing InGuinal Hernia Trial (RIGHT Trial): The Evaluation of Sex Hormones to Reverse Inguinal Hernias in Males","RIGHT","Inclusion Criteria:\n\n* Male sex\n* Age ≥ 50 years at time of enrollment\n* Symptomatic unilateral inguinal hernia confirmed on physical examination\n* Hernia visible \u002F confirmed on groin ultrasound\n* Non-recurrent inguinal hernia (primary hernia only)\n* Willing and able to provide written informed consent\n* Able and willing to comply with all protocol-required visits, laboratory assessments, imaging, and follow-up\n* Willing to use contraception and avoid fathering a child during study participation and for 12 months after last dose\n* Willing to be counseled regarding vitamin D and calcium supplementation Bone safety mitigation measure per PIND response.\n\nExclusion Criteria:\n\nHernia Characteristics\n\n* Scrotal hernia (any)\n* Bilateral inguinal hernia\n* Recurrent inguinal hernia (prior repair at same site)\n\nRenal \\& Hepatic\n\n* Clinically significant renal dysfunction judged by investigator to increase study risk\n* Clinically significant hepatic dysfunction at baseline\n\nHematologic\n\n■ Clinically significant baseline hematologic abnormality (including elevated hematocrit or polycythemia)\n\nUrologic \u002F Prostate\n\n* Symptomatic benign prostatic hyperplasia (BPH) requiring active medical or procedural treatment\n* Clinically significant untreated prostate disease\n\nSkeletal \u002F Bone\n\n* Baseline osteoporosis (T-score ≤ -2.5 on DEXA at any site)\n* Recent fragility fracture (within prior 12 months or as judged by investigator)\n* Other clinically significant skeletal vulnerability judged to increase risk from estrogen suppression\n\nImmunosuppression ■ Active immunosuppression (e.g., systemic corticosteroids, biologic agents, post-transplant regimens)\n\nPsychiatric\n\n■ Unstable or uncontrolled psychiatric illness that, in the investigator's judgment, would interfere with safe study participation\n\nReproductive \u002F Fertility ■ Actively pursuing fertility or planning conception during study participation\n\nPrior \u002F Concomitant Therapy\n\n* Current use of androgen replacement therapy, exogenous estrogen, or other endocrine-active agents that would confound study interpretation\n* Prior or current use of aromatase inhibitor or selective estrogen receptor modulator \u002F degrader within 6 months of enrollment\n\nGeneral\n\n■ Any other clinically significant medical condition, laboratory abnormality, or circumstance that, in the investigator's judgment, would place the participant at unacceptable risk or compromise study integrity","MALE","50 Years",{"count":19,"type":20},30,"ESTIMATED","INTERVENTIONAL",[23],"PHASE1","This is a prospective, single-center, three-arm Phase 1 safety and feasibility trial evaluating anti-estrogen therapy in men age 50 years and older with symptomatic unilateral inguinal hernias. Participants will be randomized to receive fulvestrant 250 mg intramuscularly, fulvestrant 500 mg intramuscularly, or letrozole 5 mg orally for 6 months. The study will evaluate safety, tolerability, feasibility, hormone changes, hernia size, patient-reported outcomes, bone density, and imaging-based hernia classification.",[26,27,28,29],"Inguinal Hernia Unilateral","Inguinal Hernia Bilateral","Inguinal Hernia Without Obstruction or Gangrene","Inguinal Hernia, Without Mention of Obstruction or Gangrene",[31,32,33,34,35,36,37,38,39,40,41,42,43],"inguinal hernia","hernia","fulvestrant","letrozole","anti-estrogen therapy","aromatase inhibitor","estrogen receptor","ESR1","male inguinal hernia","hormonal therapy","fibrosis","hernia prevention","hernia regression","RECRUITING","2026-06-24",{"date":47,"type":48},"2026-06-26","ACTUAL",{"date":50,"type":20},"2026-07-01",{"date":52,"type":20},"2028-06",{"name":54,"class":55},"Northwestern University","OTHER",""]